Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mai H Le

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|December 12, 2007
Polonium 210, exposedMai H Le
Therapeutic Advances in Medical Oncology|July 2, 2019
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumorsRobert Wesolowski, Neelesh Sharma, Laura Reebel, et al.
Cancer Immunology Research|December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell ResponsesSamantha K Greaney, Alain P Algazi, Katy K Tsai, et al.
Immunotherapy|October 25, 2017
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)David A Canton, Shawna Shirley, Jocelyn Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaCatherine C Smith, Aaron D Viny, Evan Massi, et al.
Immunity|September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Immunity|December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|December 12, 2007
Polonium 210, exposedMai H Le
Therapeutic Advances in Medical Oncology|July 2, 2019
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumorsRobert Wesolowski, Neelesh Sharma, Laura Reebel, et al.
Cancer Immunology Research|December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell ResponsesSamantha K Greaney, Alain P Algazi, Katy K Tsai, et al.
Immunotherapy|October 25, 2017
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)David A Canton, Shawna Shirley, Jocelyn Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaCatherine C Smith, Aaron D Viny, Evan Massi, et al.
Immunity|September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Immunity|December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Pageof 2